NEOGENOMICS INC

NeoGenomics, Inc. announced that Alicia Olivo, Executive Vice President, General Counsel & Business Development, will transition from her role. Her last day as General Counsel will be September 21, 2026, and she will remain an employee until October 2, 2026, for transition. Ms. Olivo will be eligible for separation payments and benefits as per her employment agreement.

NeoGenomics reported a significant financial turnaround for Q2 2026, achieving a net income of $2.24 million, or $0.02 per share, compared to a substantial loss in the prior year. Revenue increased by 11.2% to $201.66 million. The company also completed a debt refinancing, issuing $316.3 million in new convertible senior notes and repaying $262.89 million of existing notes, resulting in an $11.18 million gain on debt extinguishment.

NeoGenomics reported strong second-quarter 2026 results, with total revenue increasing 11% year-over-year to $202 million and GAAP net income reaching $2 million. Adjusted EBITDA grew 36% to $14 million. The company also raised its full-year 2026 revenue and adjusted EBITDA guidance, reflecting consistent operating and financial performance. Key business developments included strengthening its capital structure through a $316 million convertible senior notes offering and finalizing a civil settlement with the Department of Justice.

NeoGenomics, Inc. announced a civil settlement with the U.S. Department of Justice (DOJ) on behalf of the Office of Inspector General of the U.S. Department of Health and Human Services (OIG-HHS). The settlement resolves an investigation into the company's consulting services provided to healthcare providers, which NeoGenomics had voluntarily self-disclosed in November 2021. The company agreed to pay $9,813,260 plus interest, which is less than the $11.2 million reserve previously accrued for the matter. CEO Tony Zook expressed satisfaction with resolving this legacy issue.

NeoGenomics, Inc. completed its offering of 0.75% Convertible Senior Notes due 2032, totaling $316.25 million in aggregate principal amount after initial purchasers exercised their option for additional notes. The notes have an initial conversion price of approximately $14.16 per share, representing a 35.0% premium over the last reported sale price. To mitigate potential dilution and offset cash payments upon conversion, the company also entered into capped call transactions with a cap price of $20.98 per share.

NeoGenomics, Inc. announced the pricing of its offering of $275 million in aggregate principal amount of 0.75% convertible senior notes due 2032. The offering, made to qualified institutional buyers, includes an option for an additional $41.25 million. The company also plans to use a portion of the net proceeds to repurchase $276 million of its existing convertible senior notes due 2028 and up to $25 million of its common stock.

NeoGenomics, Inc. announced the commencement of a proposed offering of $275 million in convertible senior notes due 2032 to qualified institutional buyers. The company may also grant an option for an additional $41.25 million in notes. Proceeds are intended for capped call transactions, repurchasing existing 0.25% convertible senior notes due 2028, and repurchasing up to $25 million of its common stock. The offering is subject to market conditions.

NeoGenomics, Inc. held its Annual Meeting on May 21, 2026, where stockholders approved an amendment to the 2023 Equity Incentive Plan, increasing authorized shares by 5,000,000. All nine director nominees were elected, and the compensation of Named Executive Officers received advisory approval. Additionally, Deloitte & Touche LLP was ratified as the independent registered public accountant.

NEOGENOMICS INC reported a significant narrowing of its net loss in Q1 2026, reaching $(17.1) million compared to $(25.9) million in the prior year, alongside an 11.1% increase in net revenue to $186.7 million. The company also saw a substantial improvement in net cash used in operating activities, which decreased to $(8.1) million from $(25.3) million year-over-year. This quarter's results reflect ongoing efforts to improve financial performance following the acquisition of Pathline in April 2025 and the divestment of Trapelo Health in December 2025.

NeoGenomics, Inc. reported strong first quarter 2026 results, with total revenue increasing 11% year-over-year to $187 million, driven by a 14% rise in clinical revenue. The company significantly reduced its net loss by 34% to $17 million and achieved positive Adjusted EBITDA of $9 million, a 27% increase. Operational highlights include the launch of RaDaR® ST MRD assay and PanTracer Pro, alongside favorable MolDX coverage for PanTracer™ LBx. Consequently, NeoGenomics raised its full-year 2026 revenue guidance to a range of $797-$803 million.